209 related articles for article (PubMed ID: 30195804)
1. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
[TBL] [Abstract][Full Text] [Related]
2. Population-Based Analysis of Breast Cancer Incidence and Survival Outcomes in Women Diagnosed with Lobular Carcinoma In Situ.
Wong SM; King T; Boileau JF; Barry WT; Golshan M
Ann Surg Oncol; 2017 Sep; 24(9):2509-2517. PubMed ID: 28455673
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database.
Li S; Yang J; Shen Y; Zhao X; Zhang L; Wang B; Li P; Wang Y; Yi M; Yang J
BMC Public Health; 2019 Nov; 19(1):1592. PubMed ID: 31783815
[TBL] [Abstract][Full Text] [Related]
4. Survival Outcomes and Pathologic Features Among Breast Cancer Patients Who Have Developed a Contralateral Breast Cancer.
Liederbach E; Wang CH; Lutfi W; Kantor O; Pesce C; Winchester DJ; Yao K
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S412-21. PubMed ID: 26334294
[TBL] [Abstract][Full Text] [Related]
5. Secondary gastric cancer malignancies following a breast cancer diagnosis: A population-based analysis.
Mahar AL; Kagedan DJ; Hallet J; Coburn NG
Breast; 2017 Jun; 33():34-37. PubMed ID: 28279886
[TBL] [Abstract][Full Text] [Related]
6. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
[TBL] [Abstract][Full Text] [Related]
7. Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.
Jamy O; Sarmad R; Costa L
Leuk Res; 2019 Jul; 82():1-6. PubMed ID: 31108340
[TBL] [Abstract][Full Text] [Related]
8. Hepatosteatosis may predict late recurrence of breast cancer: A single-center observational study.
Kus T; Cinkir HY; Aktas G; Abali H
Curr Probl Cancer; 2019 Dec; 43(6):100461. PubMed ID: 30686567
[TBL] [Abstract][Full Text] [Related]
9. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America.
Karalexi MA; Baka M; Ryzhov A; Zborovskaya A; Dimitrova N; Zivkovic S; Eser S; Antunes L; Sekerija M; Zagar T; Bastos J; Demetriou A; Agius D; Florea M; Coza D; Polychronopoulou S; Stiakaki E; Moschovi M; Hatzipantelis E; Kourti M; Graphakos S; Pombo-de-Oliveira MS; Adami HO; Petridou ET
Eur J Cancer; 2016 Nov; 67():183-190. PubMed ID: 27677054
[TBL] [Abstract][Full Text] [Related]
10. Trends in all-cause mortality among patients with chronic myeloid leukemia: a Surveillance, Epidemiology, and End Results database analysis.
Brunner AM; Campigotto F; Sadrzadeh H; Drapkin BJ; Chen YB; Neuberg DS; Fathi AT
Cancer; 2013 Jul; 119(14):2620-9. PubMed ID: 23625575
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
12. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
14. Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.
Wei JL; Jiang YZ; Shao ZM
Int J Clin Oncol; 2019 Aug; 24(8):934-940. PubMed ID: 30888527
[TBL] [Abstract][Full Text] [Related]
15. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
Kaplan H; Malmgren J; De Roos AJ
Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia.
Wang H; Yin Y; Wang R; Huang J; Xue H; Cheng Y; Zhang L; Chen C
BMC Cancer; 2020 Nov; 20(1):1081. PubMed ID: 33172389
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Aguiar RC
Leuk Lymphoma; 1998 Mar; 29(1-2):17-26. PubMed ID: 9638972
[TBL] [Abstract][Full Text] [Related]
18. US breast cancer mortality trends in young women according to race.
Ademuyiwa FO; Gao F; Hao L; Morgensztern D; Aft RL; Ma CX; Ellis MJ
Cancer; 2015 May; 121(9):1469-76. PubMed ID: 25483625
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study.
Wang K; Zhu GQ; Shi Y; Li ZY; Zhang X; Li HY
Clin Breast Cancer; 2019 Feb; 19(1):e101-e115. PubMed ID: 30502219
[TBL] [Abstract][Full Text] [Related]
20. Leukemia incidence following primary breast carcinoma treatment.
Kaplan HG; Malmgren JA; Atwood M
Cancer; 2004 Oct; 101(7):1529-36. PubMed ID: 15378478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
